KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis …
2022年9月29日 · To overcome self-recognition of trogocytic antigen (TROG-antigen)-expressing (TROG +) NK cells by the activating CAR (aCAR), we designed an inhibitory CAR (iCAR) against an NK-specific antigen...
Verismo Therapeutics: KIR-CAR T Cell Therapy for Solid Tumors
Verismo is pioneering the further development of novel chimeric antigen receptors (CARs) to more realistically reflect the design of killer immunoglobulin-like receptors (KIRs), creating SynKIR™. Based on NK cell receptors, KIR-CAR naturally overcomes T cell exhaustion.
Generation of Potent T-cell Immunotherapy for Cancer Using …
We show that this simple, KIR-based CAR (KIR-CAR) triggers robust antigen-specific proliferation and effector function in vitro when introduced into human T cells with DAP12, an immunotyrosine-based activation motifs-containing adaptor.
Nat Med：双靶向CAR NK细胞有望阻止NK细胞功能衰竭和肿瘤逃 …
相关研究结果发表在2022年10月的Nature Medicine期刊上，论文标题为“KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape”。 这项新的研究表明，一种称为“胞啃作用（trogocytosis）”的正常生理过程通过导致肿瘤抗原丢失、CAR NK细胞 …
KIR-CAR，CAR-T 之父领衔开创的变种CAR技术进入1期临床
2023年6月17日 · SynKIR是Verismo公司开发的 双链CAR-T细胞疗法，使用T细胞或NK细胞的结合物KIR来刺激蛋白与细胞接触，激活它并促使它杀死肿瘤细胞，哪怕身处极具挑战性的实体瘤环境中，也能够保持抗肿瘤T细胞活性，有效地识别并将其杀灭。 Verismo公司公布的管线中只有SynKIR-310一枝独秀用于治疗血液瘤， 其余都选择了实体瘤作为适应症，这也从侧面展现了Verismo在血液瘤、实体瘤两手抓的全面布局下，仍侧重于攻克临床未满足领域。 Verismo在 …
间皮瘤KIR-CAR T细胞免疫疗法动态：SynKIR-110获孤儿药称号
kir-car平台是一种双链car t细胞疗法，并已在临床前模型中被证明能够保持 抗肿瘤t细胞 活性，甚至在具有挑战性的实体瘤环境中。 基于 自然杀伤细胞 受体，KIR-CAR为T细胞提供自然的开关刺激，而不会引发T细胞衰竭。
Platform - Verismo Therapeutics: Revolutionizing KIR-CAR Therapy
The KIR-CAR platform (SynKIR™) is the first CAR T cell therapy with long-term T cell functionality. Its naturally-inspired unique structure designed to couple and decouple to allow T cells to remain effective even under repeated tumor encounters in the harshest of solid tumor microenvironments.
Targeting KIR as a novel approach to improve CAR-NK cell function
These pre-clinical studies demonstrate the potential utility of targeting the KIR to improve CAR-NK cell efficacy and patient outcomes. Keywords: Killer immunoglobulin-like receptors (KIRs), natural killer cells (NK cells), chimeric antigen receptor (CAR), immunotherapy, CAR-NK cells.
首次在人体试验中评估KIR-CAR T细胞疗法通过申请 - Pharmcube
kir-car平台技术是专门为晚期实体瘤开发，该平台是一种双链car-t细胞疗法，临床前模型已被证明即使在具有挑战性的实体瘤环境中也能够保持抗肿瘤t细胞活性。
新锐！源于宾大，3300万美元融资，开发双链CAR-T疗法医药新闻 …
2023年3月1日 · Verismo新型KIR-CAR平台是一种双链CAR-T细胞疗法，旨在在具有挑战性的实体瘤环境中保持活性。2023年将其第一项资产带入首次人体临床试验。Verismo是唯一一家开发KIR-CAR平台的公司，该平台是一种改良的NK样受体，旨在提高对抗侵袭性实体瘤的持久性和疗效。